TrialSignal
Clinical trial intelligence report
Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05194592
Status
UNKNOWN
Phase
PHASE4
Sponsor
Wonju Severance Christian Hospital
Executive brief
Investment-Ready Snapshot
Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes is a PHASE4 clinical asset sponsored by Wonju Severance Christian Hospital in Type2 Diabetes, Remodeling, Ventricular. SEO and diligence focus: Dapagliflozin, Gemigliptin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05194592
Indication
Type2 Diabetes
Modality
small molecule
Target
Dapagliflozin, Gemigliptin
Intervention
Dapagliflozin, Gemigliptin
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.